Zusammenfassung
Ziel: Verschiedene Ultraschall- und biochemische Methoden werden zur Bestimmung des Risikos der chromosomalen Aberrationen benutzt. Das Ziel unserer Arbeit war die Schaffung eines diagnostischen Schemas von größter Sensitivität mithilfe eines Algorithmus, der die Ultraschallparameter beinhaltet. Material und Methoden: In einer Population von 1490 schwangeren Frauen wurde eine Ultraschalluntersuchung inklusive Nackentransparenz und Nasenbein im ersten Trimester durchgeführt. Im frühen zweiten Trimester wurde eine weitere Ultraschalluntersuchung mit der Messung von Nackentransparenz und Nasenbein vorgenommen. Ergebnisse: Eine Kombination von NT- und NB-Messung zeigte die größte Sensitivität (94,7 %), Spezifität (99,21 %), PPV (85,7 %) und NPV (99,73 %). Schlussfolgerung: Der vorgeschlagene Test ist charakterisiert durch einen hohen prädiktiven Wert für die Entdeckung der chromosomalen Aberrationen, niedrige Ausführungskosten sowie absolute Sicherheit für den Fetus und er kann allen schwangeren Frauen angeboten werden. Diese Kombination von 2 Ultraschalluntersuchungen erhöht die Wertigkeit des Testes erheblich.
Abstract
Purpose: Different sonographical and biochemical methods for the detection of an elevated risk of chromosomal abnormality are used. The aim of our study was to establish a diagnostic scheme with the highest sensitivity by means of an algorithm incorporating all parameters. Materials and Methods: In a group of 1490 pregnant women, ultrasound examination including nuchal translucency and nasal bone measurement was performed in the first trimester. Then, in the early second trimester, a second ultrasound examination combined with measuring nuchal thickness and nasal bone was carried out. Results: The combination of the NT and NB measurement showed the highest sensitivity (94.7 %), specificity (99.21 %), PPV (85.7 %) and NPV (99.73 %). Conclusion: The proposed integrated test is characterised by a high predictive value for the detection of chromosomal abnormalities, low cost of performance and absolute safety for the foetus and could be offered to all pregnant women. The combination of two ultrasound examinations and biochemistry greatly increased the value of the test.
Key words
nuchal translucency - ultrasound 2D - chromosomal aberration - Down syndrome - screening
References
1
Benacerraf B R, Frigoletto F D, Laboda L A.
Sonographic diagnosis of Down syndrome in the second trimester.
Am J Obstet Gynecol.
1985;
153
49-52
2
Szabo J, Gellen J.
Nuchal fluid accumulation in trisomy 21 detected by vaginal sonography in first trimester.
Lancet.
1990;
336
1133
3
Nicolaides K H, Azar G, Byrne D. et al .
Fetal nuchal translucency: ultrasound screening for chromosomal defects in the first trimester of pregnancy.
Br Med J.
1992;
304
867-889
4
Snijders R JM, Noble P, Sebire N. et al .
UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10 - 14 weeks of gestation.
Lancet.
1998;
351
343-346
5
Pajkrt E, Lith J M, Mol B W. et al .
Screening for Down‘s syndrome by fetal nuchal translucency measurement in a general obstetric population.
Ultrasound Obstet Gynecol.
1998;
12
163-169
6
Keeling J W, Hansen B F, Kjaer van I.
Pattern of malformations in the axial skeleton in human trisomy 21 fetuses.
Am J Med Genet.
1997;
68
466-471
7
Stempfle N, Huten Y, Fredouille C. et al .
Skeletal abnormalities in fetuses with Down’s syndrome: a radiographic post-mortem study.
Pediatr Radiol.
1999;
29
682-688
8
Cicero S, Curcio P, Papageorghiou A. et al .
Absence of nasal bone in fetuses with trisomy 21 at 11 - 14 weeks of gestation: an observational study.
Lancet.
2001;
358
1665-1667
9
Bromley B, Lieberman E, Shipp T D. et al .
Fetal nose bone length: a marker for Down syndrome in the second trimester.
J Ultrasound Med.
2002;
21
1387-1394
10
Orlandi F, Bilardo C M, Campogrande M. et al .
Measurement of nasal bone length at 11 - 14 weeks of pregnancy and its potential role in Down syndrome risk assessment.
Ultrasound Obstet Gynecol.
2003;
22
36-39
11 Nicolaides K H, Sebire N J, Snijders R JM. The 11 - 14 week scan. The diagnosis of fetal abnormalities. Diploma in Fetal Medicine Series. London; New York; The Parthenon Publishing Group 1999
12
Tercanli S, Holzgreve W, Batukan C. et al .
Screening for aneuploidy by first trimester nuchal translucency measurement: results from a prospective trial including 1980 cases in a single center in Switzerland.
Ultraschall in Med.
2002;
23
22-26
13
Bromley B, Lieberman E, Shipp T D. et al .
The genetic sonogram: a method of risk assessment for Down syndrome in the second trimester.
J Ultrasound Med.
2002;
21
1087-1096
14
Kornman L H, Morssink L P, Beekhuis J R. et al .
Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice.
Prenat Diagn.
1996;
16
797-805
15
Malone F D, Berkowitz R L, Canick J A. et al .
First trimester screening for aneuploidy: research or standard of care?.
Am J Obstet Gynecol.
2000;
182
490-496
16
Nyberg D A, Souter V L.
Sonographic markers of fetal trisomies: second trimester.
J Ultrasound Med.
2001;
20
655-674
17
Gilbert R, Augood C, Gupta R. et al .
Screening for Down’s syndrome: effects, safety, and cost effectiveness of first and second trimester strategies.
BMJ.
2001;
323
423-425
18
Petrou S, Henderson J, Roberts T. et al .
Recent economic evaluations of antenatal screening: a systematic review and critique.
J Med Screen.
2000;
7
59-73
19
Cicero S, Sonek J D, McKenna D S. et al .
Nasal bone hypoplasia in trisomy 21 at 15 - 22 weeks gestation.
Ultrasound Obstet Gynecol.
2003;
21
15-18
20
Bewley S, Roberts L J, Mackinson M. et al .
First trimester fetal nuchal translucency: problems with screening general population.
BJOG.
1995;
102
386-388
21
Braithwaite J M, Morris R W, Economides D L.
Nuchal translucency measurements: frequency distribution and changes with gestation in a general population.
Br J Obstet Gynecol.
1996;
103
1201-1204
22
Lee W, DeVore G R, Comstock C H. et al .
Nasal bone evaluation in fetuses with Down syndrome during the second and third trimesters of pregnancy.
J Ultrasound Med.
2003;
22
55-60
23
Vintzileos A, Walters C, Yeo L.
Absent nasal bone in the prenatal detection of fetuses with trisomy 21 in a high-risk population.
Obstet Gynecol.
2003;
101
905-908
24
Vergani P, Locatelli A, Piccoli M G. et al .
Best second trimester sonographic markers for the detection of trisomy 21.
J Ultrasound Med.
1999;
18
469-473
25
Kanellopoulos V, Katsetos C, Economides D L.
Examination of fetal nasal bone and repeatability of measurement in early pregnancy.
Ultrasound Obstet Gynecol.
2003;
22
131-134
26
Zoppi M A, Ibba R M, Axiana C. et al .
Absence of fetal nasal bone and aneuploidies at first-trimester nuchal translucency screening in unselected pregnancies.
Prenat Diagn.
2003;
23
496-500
27
Cuckle H.
Time for total shift to first-trimester screening for Down’s syndrome.
The Lancet.
2001;
358
9294
28
Sieroszewski P, Suzin J, Ba-Budecka E.
Diagnostic schema for fetal malformations in the first half of pregnancy.
Ginekologia Polska.
2003;
10
1276-1283 (in Polish)
29
Bettelheim D, Ulm M R, Deutinger J. et al .
Echogenic intracardiac structures (golf ball phenomenon) as predictors of chromosome anomalies.
Ultraschall in Med.
1999;
20
19-21
30
Vintzileos A M, Egan J F.
Adjusting the risk for trisomy 21 on the basis of second trimester ultrasonography.
Am J Obstet Gynecol.
1995;
172
837-844
31
Nicolaides K H, Snijders R JM, Gosden C M.
Ultrasonographically detectable markers of fetal chromosomal abnormalities.
Lancet.
1992;
340
704-707
32
Wald M, Lawrenz K, Deutinger J. et al .
Verification of anomalies of the central nervous system detected by prenatal ultrasound.
Ultraschall in Med.
2004;
25
214-217
Dr. Piotr Sieroszewski
Dep. of Ultrasound in Obstetrics and Gynaecology, Medical University of Lodz
94 - 029 Lodz
Phone: ++48/42/6 80 47 22
Fax: ++48/42/6 86 04 71
Email: advances@csk.umed.lodz.pl